Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 21, 2022 08:05 ET | Source: MaxCyte, Inc

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor

Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities. ROCKVILLE, Md., Sept....
September 07, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
August 10, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- MaxCyte,...
July 15, 2022 08:00 ET | Source: MaxCyte, Inc

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
July 12, 2022 08:00 ET | Source: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
May 13, 2022 16:30 ET | Source: MaxCyte, Inc

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
May 09, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte Reports First Quarter Financial Results

GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
May 03, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
April 20, 2022 16:05 ET | Source: MaxCyte, Inc

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to...
April 15, 2022 09:00 ET | Source: MaxCyte, Inc

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform...